Immunocompromised Patients Clinical Trial
Official title:
Evaluation Aof Safety and Immunogenicity of Non-adjuvanted Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants, Produced by Butantan Institute
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants. The primary immunological endpoint is to analyze the proportion of subjects with antibody titers of 1:40 or more on hemagglutination-inhibition assay 21 days after 1 dose of the vaccine. Volunteers will be monitored for safety during 21 days after vaccination. Volunteers will be recruited based on inclusion and exclusion criteria. Vaccine composition is: 15 micrograms of split inactivated virus (A/California/7/2009 (H1N1) (NYMC X179A). The hypothesis of the study is that the vaccine is safe and immunogenic in the volunteers recruited.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05605145 -
PCP in Immunocompromised Population in Southern China
|
||
| Recruiting |
NCT05439044 -
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
|
||
| Recruiting |
NCT05726006 -
Invasive Group B Streptococcus Disease Burden and Its Antimicrobial Resistance in Malaysia Among Non-pregnant Adults.
|
||
| Not yet recruiting |
NCT04680884 -
Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial
|
Phase 3 | |
| Not yet recruiting |
NCT02983851 -
Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure
|
N/A | |
| Completed |
NCT04805125 -
Immunocompromised Swiss Cohorts Based Trial Platform
|
Phase 3 |